{"id":380706,"date":"2020-11-13T07:33:27","date_gmt":"2020-11-13T12:33:27","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380706"},"modified":"2020-11-13T07:33:27","modified_gmt":"2020-11-13T12:33:27","slug":"fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\/","title":{"rendered":"Fulcrum Therapeutics to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE,\u00a0Mass., Nov.  13, 2020  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SqsxRl8Nt1ZAvQYkXacEhh7IOiVSSmNzq44LVmVx9OZFVIWURxWLT9_9JgoBjbGlbn7qKvgFPAK0y8B2_7FSo8dsDXfn9tl1hfNac9O03lM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>Fulcrum Therapeutics, Inc.<\/strong><\/a>\u00a0(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Stifel Virtual 2020 Healthcare Conference<br \/><\/strong>Presentation on Wednesday, November 18, 2020 at 11:20 a.m. ET.<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Piper Sandler 32nd Annual Virtual Healthcare Conference<br \/><\/strong>Prerecorded Fireside Chat Available on Monday, November 23, 2020 at 10:00 a.m. ET<\/li>\n<\/ul>\n<p>Audio webcasts of the presentations will be available through the Investor Relations section of the Fulcrum website at https:\/\/ir.fulcrumtx.com\/events-and-presentations. Archived replays will be available on the Company\u2019s website for 90 days after each conference.<\/p>\n<p>\n        <strong>About Fulcrum Therapeutics <\/strong><br \/>\n        <br \/>Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum\u2019s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and Phase 3 for the treatment of COVID-19. Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta thalassemia into Phase 1 clinical development.<\/p>\n<p>Please visit www.fulcrumtx.com.<\/p>\n<p>\n        <strong>C<\/strong><br \/>\n        <strong>ontact:<\/strong><br \/>\n        <br \/>Christi Waarich<br \/>Director, Investor Relations <br \/>and Corporate Communications<br \/>617-651-8664<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oC1QragICTkCvtD3DkKAlj79XIloW5kuZ_sZCU5hkNtfeJ7zmut6H69AZ_AbC9F_1WdMte3URlPeHv9LGlupYatcGiMemt37yY698zfn7M0=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">cwaarich@fulcrumtx.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTc5OCMzODI2NDAyIzIxODM1NDI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/5bd63887-d7f0-4b3e-b642-c71ca0398241\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE,\u00a0Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; Fulcrum Therapeutics, Inc.\u00a0(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences: Stifel Virtual 2020 Healthcare ConferencePresentation on Wednesday, November 18, 2020 at 11:20 a.m. ET. Piper Sandler 32nd Annual Virtual Healthcare ConferencePrerecorded Fireside Chat Available on Monday, November 23, 2020 at 10:00 a.m. ET Audio webcasts of the presentations will be available through the Investor Relations section of the Fulcrum website at https:\/\/ir.fulcrumtx.com\/events-and-presentations. Archived replays will be available on the Company\u2019s website for 90 days after each conference. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Fulcrum Therapeutics to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-380706","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fulcrum Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fulcrum Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE,\u00a0Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; Fulcrum Therapeutics, Inc.\u00a0(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences: Stifel Virtual 2020 Healthcare ConferencePresentation on Wednesday, November 18, 2020 at 11:20 a.m. ET. Piper Sandler 32nd Annual Virtual Healthcare ConferencePrerecorded Fireside Chat Available on Monday, November 23, 2020 at 10:00 a.m. ET Audio webcasts of the presentations will be available through the Investor Relations section of the Fulcrum website at https:\/\/ir.fulcrumtx.com\/events-and-presentations. Archived replays will be available on the Company\u2019s website for 90 days after each conference. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the &hellip; Continue reading &quot;Fulcrum Therapeutics to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-13T12:33:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTc5OCMzODI2NDAyIzIxODM1NDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Fulcrum Therapeutics to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2020-11-13T12:33:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/\"},\"wordCount\":238,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTc5OCMzODI2NDAyIzIxODM1NDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/\",\"name\":\"Fulcrum Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTc5OCMzODI2NDAyIzIxODM1NDI=\",\"datePublished\":\"2020-11-13T12:33:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTc5OCMzODI2NDAyIzIxODM1NDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTc5OCMzODI2NDAyIzIxODM1NDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fulcrum Therapeutics to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fulcrum Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\/","og_locale":"en_US","og_type":"article","og_title":"Fulcrum Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"CAMBRIDGE,\u00a0Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; Fulcrum Therapeutics, Inc.\u00a0(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences: Stifel Virtual 2020 Healthcare ConferencePresentation on Wednesday, November 18, 2020 at 11:20 a.m. ET. Piper Sandler 32nd Annual Virtual Healthcare ConferencePrerecorded Fireside Chat Available on Monday, November 23, 2020 at 10:00 a.m. ET Audio webcasts of the presentations will be available through the Investor Relations section of the Fulcrum website at https:\/\/ir.fulcrumtx.com\/events-and-presentations. Archived replays will be available on the Company\u2019s website for 90 days after each conference. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the &hellip; Continue reading \"Fulcrum Therapeutics to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-13T12:33:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTc5OCMzODI2NDAyIzIxODM1NDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Fulcrum Therapeutics to Participate in Upcoming Investor Conferences","datePublished":"2020-11-13T12:33:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\/"},"wordCount":238,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTc5OCMzODI2NDAyIzIxODM1NDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\/","name":"Fulcrum Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTc5OCMzODI2NDAyIzIxODM1NDI=","datePublished":"2020-11-13T12:33:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTc5OCMzODI2NDAyIzIxODM1NDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTc5OCMzODI2NDAyIzIxODM1NDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-upcoming-investor-conferences-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Fulcrum Therapeutics to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380706","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=380706"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380706\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=380706"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=380706"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=380706"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}